Oral Ozempic and Wegovy pills are now available for same-day delivery on Amazon. Novo Nordisk CEO says more than one million ...

Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for ...

Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy ...

Record-breaking launch: Wegovy pill reached over 2 million U.S. prescriptions in 16 weeks, generating $355 million in Q1 sales and doubling analyst forecasts. New patients drive growth: Around 80% of ...

FRIDAY, May 8, 2026 (Health Day News) — Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription for ...

Record-breaking launch: Wegovy pill sales nearly doubled forecasts in Q1 2026, with over 2 million prescriptions since launch. Guidance revised: Novo Nordisk now expects smaller 2026 sales and profit ...

Guidance changed upward: Q4 2025 guidance was “$750 million to $780 million” revenue and “at least $230 million” adjusted EBITDA, while Q1 2026 guidance moved to “$765 million to $785 million” and “at ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...

Common side effects of Ozempic in both pill and injection form include abdominal pain, constipation, diarrhea and nausea.